Skip to main content
Fig. 2 | Trials

Fig. 2

From: Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial

Fig. 2

STAR study schema. Refer to Fig. 1 for study agent administration and dosing details. The asterisk (*) symbol indicates the following: 12-week safety follow-up (F/U) period begins at W48 after final study drug administration. EE, early escape; F/U, follow-up; GUS, guselkumab; MRI, magnetic resonance imaging; PBO, placebo; PE, primary endpoint; Q4W, every 4 weeks; Q8W, every 8 weeks; R, randomization; SC, subcutaneous; SI, sacroiliac; W, week

Back to article page

Trials

ISSN: 1745-6215